Revolution Medicines (RVMD) – Analysts’ Recent Ratings Updates

A number of research firms have changed their ratings and price targets for Revolution Medicines (NASDAQ: RVMD):

• 7/9/2026 – Revolution Medicines had its price target raised by Guggenheim from $205.00 to $235.00. They now have a “buy” rating on the stock.
• 7/6/2026 – Revolution Medicines had its “buy” rating reaffirmed by HC Wainwright. They now have a $195.00 price target on the stock.
• 7/6/2026 – Revolution Medicines had its price target raised by Mizuho from $185.00 to $215.00. They now have an “outperform” rating on the stock.
• 7/2/2026 – Revolution Medicines had its price target raised by Wedbush from $165.00 to $181.00. They now have an “outperform” rating on the stock.
• 6/30/2026 – Revolution Medicines had its price target raised by Truist Financial Corporation from $179.00 to $210.00. They now have a “buy” rating on the stock.
• 6/29/2026 – Revolution Medicines had its price target raised by Needham & Company LLC from $183.00 to $235.00. They now have a “buy” rating on the stock.
• 6/2/2026 – Revolution Medicines had its price target raised by Royal Bank Of Canada from $165.00 to $182.00. They now have an “outperform” rating on the stock.
• 6/1/2026 – Revolution Medicines had its price target raised by HC Wainwright from $169.00 to $195.00. They now have a “buy” rating on the stock.
• 6/1/2026 – Revolution Medicines had its “outperform” rating reaffirmed by Wedbush.
• 6/1/2026 – Revolution Medicines had its price target raised by Oppenheimer Holdings, Inc. from $165.00 to $195.00. They now have an “outperform” rating on the stock.
• 5/21/2026 – Revolution Medicines is now covered by Sanford C. Bernstein. They set a “market perform” rating and a $151.00 price target on the stock.
• 5/21/2026 – Revolution Medicines was upgraded by Sanford C. Bernstein to “hold”.

Insider Transactions at Revolution Medicines

In related news, CFO Jack Anders sold 20,000 shares of the company’s stock in a transaction that occurred on Wednesday, June 24th. The shares were sold at an average price of $168.33, for a total transaction of $3,366,600.00. Following the completion of the transaction, the chief financial officer directly owned 123,269 shares in the company, valued at $20,749,870.77. This represents a 13.96% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Sushil Patel sold 5,580 shares of the stock in a transaction that occurred on Monday, June 29th. The shares were sold at an average price of $187.99, for a total transaction of $1,048,984.20. Following the completion of the transaction, the director directly owned 21,656 shares of the company’s stock, valued at approximately $4,071,111.44. The trade was a 20.49% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders have sold 132,497 shares of company stock valued at $21,470,486. 7.60% of the stock is owned by company insiders.

Revolution Medicines is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapies to treat RAS-dependent cancers and other diseases driven by the RAS/MAPK pathway. The company’s research efforts target historically “undruggable” proteins, aiming to inhibit critical nodes in cell signaling that promote tumor growth and therapeutic resistance.

The lead pipeline includes RMC-4630, a SHP2 inhibitor; RMC-6291, a selective KRAS G12C inhibitor; and RMC-6236, a pan-RAS inhibitor designed to address multiple RAS mutations.